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Development of a novel risk 
score to predict mortality 
in patients admitted to hospital 
with COVID‑19
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Patients hospitalised with COVID‑19 have a high mortality. Identification of patients at increased risk 
of adverse outcome would be important, to allow closer observation and earlier medical intervention 
for those at risk, and to objectively guide prognosis for friends and family of affected individuals. 
We conducted a single‑centre retrospective cohort study in all‑comers with COVID‑19 admitted to 
a large general hospital in the United Kingdom. Clinical characteristics and features on admission, 
including observations, haematological and biochemical characteristics, were used to develop a 
score to predict 30‑day mortality, using multivariable logistic regression. We identified 316 patients, 
of whom 46% died within 30‑days. We developed a mortality score incorporating age, sex, platelet 
count, international normalised ratio, and observations on admission including the Glasgow Coma 
Scale, respiratory rate and blood pressure. The score was highly predictive of 30‑day mortality with 
an area under the receiver operating curve of 0.7933 (95% CI 0.745–0.841). The optimal cut‑point was 
a score ≥ 4, which had a sensitivity of 78.36% and a specificity of 67.59%. Patients with a score ≥ 4 
had an odds ratio of 7.6 for 30‑day mortality compared to those with a score < 4 (95% CI 4.56–12.49, 
p < 0.001). This simple, easy‑to‑use risk score calculator for patients admitted to hospital with COVID‑
19 is a strong predictor of 30‑day mortality. Whilst requiring further external validation, it has the 
potential to guide prognosis for family and friends, and to identify patients at increased risk, who may 
require closer observation and more intensive early intervention.
Abbreviations
AUC  Area under the receiver operating curve
CI  Confidence interval
COVID-19  Corona virus disease 2019
ICU  Intensive care unit
IQR  Interquartile range
mSIC  Modified sepsis-induced coagulopathy
OR  Odds ratio
PPV  Positive predictive value
qSOFA  Quick sequential organ failure assessment
ROC  Receiver operator characteristic curve
SARS-CoV-2  Severe acute respiratory syndrome coronavirus 2
SIC  Sepsis-induced coagulopathy
SOFA  Sequential organ failure assessment
The Corona virus disease 2019 (COVID-19) pandemic, originating in China in late 2019, has affected over 6.8 
million people with more than 400,000 deaths  worldwide1. This disease, caused by the severe acute respira-
tory syndrome coronavirus 2 (SARS-CoV-2)2, has impacted and placed tremendous strains even on the best 
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healthcare systems in the world, due to its high infectivity and transmission rates and in some patients, a rapid 
clinical deterioration resulting in acute respiratory distress syndrome and thrombotic complications, with high 
in-hospital morbidity and mortality. A meta-analysis involving 4659 hospitalised patients with an average age of 
59.8 years showed a mortality rate of 26%, with advancing age associated with increasing  risk3. A recent survey 
of 20,133 hospitalised patients with COVID-19 in the UK with a mean age of 79 years showed that only 41% of 
patients were discharged alive, 26% died, and 34% were still in  hospital4. There is, therefore, an urgent need to 
identify patients admitted to hospital with COVID-19 who are at increased risk of death, so that these patients 
can be observed more closely, receive earlier and more aggressive medical intervention, and to guide prognosis 
and possibly also resource allocation.
Since the recognition of the potential life-threatening nature of this disease, clinicians and researchers have 
come together all over the world to collate data and identify patients at risk of a more severe clinical course of 
COVID-19. Several observational studies have identified demographic and clinical risk factors such as age, male 
gender, hypertension and obesity as risk factors for severe disease progression and  death3. Earlier reports also 
indicate that patients with comorbidities including chronic obstructive pulmonary disease, cardiovascular dis-
ease, hypertension, and patients presenting with dyspnoea are vulnerable to more severe morbidity and mortality 
after  infection5,6. Most such risk factors have been identified from detecting people in the general population, 
not in hospital, who are at increased risk of becoming infected with COVID-19 or being admitted to hospital 
with the disease. These risk factors therefore identify those patients in the community who are most vulnerable, 
but not mortality risk in-hospitalised patients with COVID-19. Since the pandemic, several risk scores includ-
ing those specific to COVID-19 such as the Brescia-COVID7 and more generic sepsis-related risk scores like 
the SOFA (Sequential Organ Failure Assessment)8 or SIC (Sepsis induced coagulopathy)9 score have been used 
in clinical situations to guide management of COVID-19 patients. Furthermore, whilst a number of haemato-
logical, biochemical and radiological characteristics have also been associated with adverse  prognosis3,10, there 
is currently no easy-to-use prognostic risk score to calculate 30-day mortality in patients admitted to hospital 
with COVID-19.
It was our aim to develop a clinically friendly, easy-to-use prognostic score to predict 30-day mortality in 
patients admitted to hospital with COVID-19.
Methods
We conducted a single-centre retrospective cohort analysis of the electronic records of all patients admitted to 
East and North Hertfordshire NHS Trust, a large district general hospital in the United Kingdom, over a period 
of 3 months (10th March 2020 to 30th May 2020) with symptoms of COVID-19, as part of an approved service 
evaluation by the Research and Development board of the East and North Hertfordshire NHS Trust. Since this 
was a service evaluation by clinicians with genuine clinical access to patient records, and since only anonymised 
data was analysed, the Research and Development board of the East and North Hertfordshire NHS Trust waived 
the requirement to see patient consent. All methods were carried out in accordance with relevant institutional 
and Good Clinical Practice guidelines and regulations.
Patient population. Clinical data of all consecutive patients who were admitted to the hospital and tested 
positive for SARS-CoV2 on nasal or oropharyngeal swabs were retrospectively collected. Only patients who were 
admitted with clinical symptoms of COVID-19 were included. We excluded patients who were either admitted 
with non-COVID-19 symptoms and had incidental asymptomatic diagnosis (such as those for example with hip 
fracture without clinical features of COVID-19) and also excluded those with COVID-19 who were discharged 
from either ambulatory care or the emergency room, without admission. We excluded patients who had a termi-
nal diagnosis due to a pre-existing condition prior to admission.
Data collection. From an available registry of all patients testing positive for SARS-CoV2 in our institu-
tion, we identified those who were admitted, and then four clinicians screened this residual cohort to identify 
those that met the inclusion criteria. Any queries were resolved by consensus. Electronic patient records were 
accessed to extract basic demographics (age, gender, ethnicity), medical history, admission observations, admis-
sion blood test results including full blood count, biochemical profile, high-sensitivity C-reactive protein (hs-
CRP), coagulation screen and outcome data.
Calculation of qSOFA and mSIC scores. For each patient, the Quick Sequential Organ Failure Assess-
ment (qSOFA)  score11,12 was calculated from data on admission. This score, calculated from a combination of 
binary variables derived from clinical observations (Glasgow Coma Scale < 15, respiratory rate > 22 and systolic 
blood pressure < 100), was calculated from clinical assessment recorded on admission (Table 4).
In patients with sepsis, coagulopathy is a known predictor of adverse outcome. The Sepsis-Induced Coagu-
lopathy (SIC) scoring system was the first scoring system specifically designed for coagulation disturbances in 
sepsis. It is easy to calculate and has a high predictive value for 28-day  mortality9,13,14. The score incorporates 
points for platelet count, international normalized ratio (INR) and SOFA score. However, the SOFA score, 
in contrast to the qSOFA score, is designed for patients with severe sepsis admitted to the intensive care unit 
(ICU), and requires the measurement of the partial pressure of arterial oxygen. This is not applicable to patients 
who are not in extremis and not requiring ICU admission. Thus, in our cohort of patients, to calculate the SIC 
score, instead of using the SOFA score, we modified the SIC score to incorporate instead the qSOFA score, as 
above, and we refer to this as the modified Sepsis-Induced Coagulopathy (mSIC) score (Table 4). The mSIC 
score was obtained using the admission INR (score of 0 for INR < 1.2, 1 for INR between 1.2 and 1.4 and 2 for 
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INR > 1.4) and platelet count (score of 0 for platelets > 150 × 109/L, 1 for platelets between 100 to 150 × 109/L and 
2 for < 100 × 109/L) in conjunction with the qSOFA score.
Outcome. The primary outcome of interest was 30-day mortality. This data was captured from electronic 
medical records.
Statistical analysis. Categorical variables were summarised as proportion (number, percentage) and con-
tinuous variables as median (interquartile range, IQR). Binary variables were compared using Fisher’s exact test 
whilst continuous variables were compared using Wilcoxon rank sum test. Variables which were significantly 
different between patients that survived and those that died were entered into a univariate logistic regression 
analysis. Odds ratios (ORs) with 95% confidence interval (CI) and p-values were obtained. Continuous variables 
which were found to be significantly related to mortality were converted to a binary value, with the cut-point 
determined by receiver operating curve (ROC) analysis to obtain the area under the curve (AUC, c-statistic) 
and to identify the highest predictive value. Variables which remained statistically significant were entered into 
a multivariable logistic regression model to identify variables which remained independently associated with 
mortality. Using the ORs obtained in the multivariable regression model, we produced a COVID-19 mortality 
prediction score. The predictive ability of the COVID-19 mortality score for the primary outcome was assessed 
with ROC analysis and the c-statistic reported. Significance was taken as < 0.05. Statistical analyses were per-
formed using Stata 15 software (StataCorp, College Station, Texas, USA).
Results
A total of 486 in-patients tested positive for COVID-19 during this period, of whom 316 met the inclusion 
criteria. Out of these patients, 145 (46%) died within 30 days of hospital admission. Non-survivors were signifi-
cantly older (81 [74–88] vs. 67 [54–80] years), were more likely to be male (72.2% vs. 54.7%), with a history of 
hypertension (60% vs. 44.4%), coronary artery disease (22.1% vs. 9.4%) and atrial fibrillation (22.8% vs. 12.9%). 
They were more likely to be on oral anticoagulants on admission (24.8% vs. 10.5%). The admission blood profile 
showed significantly lower haemoglobin and higher white cell count, neutrophils, hs-CRP and INR in those who 
died compared to those who survived (Table 1). The qSOFA and mSIC score were significantly lower in those 
who survived, compared to those who died.
Predictors of 30‑day mortality. Univariate logistic regression was performed for those clinical and path-
ological variables that differed significantly on admission between patients who died and those who survived 
(Table 2), with subsequent ROC analysis for continuous variables to identify the optimal cut-point for regression 
analysis. Age had an AUC of 0.723 with the optimal cut-point of 75 years. Haemoglobin (AUC 0.421), white 
cell count (AUC 0.596), neutrophil count (AUC 0.599) and hs-CRP (AUC 0.616) had poor predictive ability as 
demonstrated on AUC analysis and were therefore not selected for logistic regression analysis.
As the mSIC score incorporated the qSOFA score and INR, these variables were not included in the regression 
model even though they were significantly different when comparing survivors and non-survivors. These were 
then entered into a multivariable logistic regression model, which showed that the variables of age ≥ 75, male 
sex and mSIC score remained independently predictive of 30-day mortality (Table 3).
Development of a COVID‑19 mortality risk score. From those variables that remained independently 
predictive of 30-day mortality on multivariable regression analysis, we developed a COVID-19 mortality score 
by weighting each characteristic based on the OR. Based on this, age ≥ 75 was given a weighting of 2 points and 
male sex a weighting of 1 point, with the mSIC score allocated points as shown in Table 4, to give a final score 
out of 10.
As the COVID-19 score increased, the 30-day mortality increased (Fig. 1). The score had an AUC of 0.793 
(95% CI 0.745–0.841) for predicting mortality, which is an improvement on both the mSIC (AUC 0.717, 95% 
CI 0.664–0.770) and the qSOFA (AUC 0.691, 95% CI 0.638–0.743) scores. The optimal cut-point with the high-
est combined sensitivity and specificity was a score of ≥ 4, which has a sensitivity of 78.36% and a specificity of 
67.59%, with a positive predictive value of 72.6% and negative predictive value of 74%. This means that patients 
with a score of ≥ 4 have a 73% chance that they will die within 30 days, and those with a score < 4 have a 74% 
chance of still being alive at 30 days (Table 5). A score of ≥ 4 had an OR of 7.55 (95% CI 4.565–12.493, p < 0.001) 
when compared to scores of < 4. 
Discussion
The ability to determine the risk of adverse outcome for people infected with SARS-CoV-2 admitted to hospital 
is very important both for the individual, in terms of highlighting the need for more intensive observation and 
earlier medical intervention, as well as to aid health care professionals to guide patients’ families in terms of 
providing some objective, although guarded, assessment of prognosis.
The COVID-19 mortality risk score we have developed provides a simple and objective way to assess 30-day 
mortality risk in patients admitted to hospital. The score is a good predictor of adverse outcome, with an AUC of 
0.793 (95% CI 0.745–0.841) and 30-day mortality increases as the COVID-19 score increases (Table 5). Patients 
with a score of ≥ 4 had an almost eightfold 30-day mortality risk when compared to those with a score of < 4 
(OR 7.55; 95% CI 4.56–12.49, p < 0.001). Physicians find positive and negative predictive values good ways to 
communicate risk, and those with a score of ≥ 4 have a 73% chance that they will die within 30 days, and those 
with a score < 4 have a 74% chance of still being alive at 30 days.
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Important strengths of our model are the inclusion of all-comers, the use of a hard clinical end-point, the 
ease-of-use and use of multivariable regression to select independent predictive markers. Such prognostic infor-
mation can be very useful for both healthcare professionals and relatives, can be easily and quickly calculated, 
and easily understood by lay individuals. The score is very simple to calculate, does not require a calculator or 
a normogram, and all the variables used in the score are routinely available, with no requirement for specific 
data from specialised tests.
Most risk score predictive models developed for COVID-19 to date have been designed for assessing risk in 
the community and risk of admission to  hospital15. One of the largest cohorts (35,463 patients) used to develop 
an in-hospital mortality score in COVID-19 is the 4C mortality  score16. It utilises several variables including 
Table 1.  Baseline patient characteristics on admission. AF Atrial Fibrillation, CKD Chronic Kidney Disease 
(defined as eGFR of less than 60 mL/min/1.73 m2), Hb Haemoglobin, WCC White cell count, CRP C-reactive 
protein, INR International normalised ratio, qSOFA quick Sepsis-related Organ Failure Assessment score, 




(n = 145) p-value
Age 67 (54–80) 81 (74–88) < 0.0001
Male sex 84 (54.7) 104 (72.2) 0.001
Ethnicity
Caucasian 155 (90.6) 134 (92.4) 0.687
Asian 10 (5.9) 4 (2.8) 0.273
Black 4 (2.3) 7 (4.8) 0.356
Mixed 2 (1.2) 0 (0) 0.50
Hypertension 76 (44.4) 87 (60.0) 0.007
Diabetes 50 (29.2) 42 (29.0) 1.00
Coronary artery disease 16 (9.4) 32 (22.1) 0.003
Dyslipidaemia 45 (26.3) 45 (31.0) 0.383
Heart failure 19 (11.1) 30 (20.7) 0.028
AF 22 (12.9) 33 (22.8) 0.025
CKD 18 (10.5) 20 (13.8) 0.391
Oral anticoagulants 18 (10.5) 36 (24.8) 0.0008
Admission bloods
Hb, g/L 133 (118–146) 126 (110–140) 0.0152
WCC, × 109/L 7.3 (5.2–10.4) 8.9 (5.8–12.1) 0.0032
Neutrophil, × 109/L 5.2 (3.82–8.6) 7.21 (4.46–10.46) 0.0024
Lymphocytes, × 109/L 0.86 (0.62–1.2) 0.83 (0.59–1.32) 0.8914
Platelets, × 109/L 210.5 (169–277) 206 (153–292) 0.2948
Hs-CRP, mg/L 72 (41–153) 121 (64–210) 0.0004
INR 1 (1–1.1) 1.1 (1–1.2) 0.0001
Severity scores
qSOFA score 1 (0–1) 1 (1–2) < 0.0001
mSIC score 1 (0–1) 2 (1–3) < 0.0001
COVID-19 mortality score 2 (1–3) 4 (3–5) < 0.0001
Table 2.  Univariate logistic regression analysis of variables that were significantly different between survivors 
and non-survivors. AF Atrial Fibrillation, mSIC modified Sepsis-Induced Coagulopathy score.
Odds ratio 95% CI p-value
Age ≥ 75 years 4.38 2.73 – 7.06 < 0.001
Male 2.20 1.37 – 3.53 0.001
Hypertension 1.88 1.20 – 2.94 0.006
Coronary artery disease 2.74 1.44 – 5.24 0.002
Heart failure 2.09 1.12 – 3.89 0.021
AF 2.00 1.10 – 3.61 0.022
Oral anticoagulants 2.81 1.51 – 5.20 0.001
mSIC score 2.35 1.81 – 3.04 < 0.001
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patient characteristics (age, gender and comorbidities), admission status (respiratory rate, oxygen saturation and 
Glasgow Coma Scale score) and blood parameters (urea and CRP). The calculation is easy with a good AUC 
(0.79 in development cohort and 0.77 in the validation cohort). This is similar to our risk score with the differ-
ence being that it predicts in-hospital, rather than 30-day, mortality. Some small studies have aimed to predict 
severity of disease progression in hospital (the latter was not clearly defined, and not mortality-based)15,17,18. A 
report in 208 patients from China, with a median age of only 44 years, described a novel scoring system to predict 
disease progression based on underlying comorbidity, age, higher LDH and lower lymphocyte  count19. However, 
disease progression was variably defined as one or more of respiratory rate ≥ 30 breaths/min, resting oxygen 
saturation ≤ 93%,  PaO2/FiO2 ≤ 300 mmHg, mechanical ventilation or worsening of lung CT findings. Mortality 
was not reported, but likely to be low given the age-group. The COVID-GRAM  score20 was developed from a 
cohort of 1590 patients in China to predict progression to critical illness which included intensive care admis-
sion, invasive ventilation or death. Although the score has shown an AUC of 0.88 in predicting risk of critical 
illness, the complexity including the requirements for a web-based calculator and various parameters including 
lactate dehydrogenase levels (which are not routinely measured in all hospitals) makes the score harder to use. 
Furthermore, the definition of “critical illness” can be nebulous and is not a hard clinical endpoint. Another early 
mortality risk score for hospitalised patients was developed from only 75 patients with COVID-19 and based on 
only age and C-reactive protein  level21. On the other hand, our risk score uses a hard clinical end-point and has 
assessed a larger generalised cohort with more comorbidities, which we feel more closely resembles the typical 
cohort admitted to hospital with COVID-19.
Hu et al. explored the use of alternative scores such as the Modified Early Warning Score and Rapid Emer-
gency Medicine Score in critically ill COVID-19 patients, which yielded satisfactory AUC (0.677 and 0.833 
respectively)22. This scoring system is applicable to only critically-ill hospitalised patients, whereas our score 
predicts mortality in all hospitalised patients. Furthermore, the reported mortality by Hu et al. was much lower 
than in our cohort (18% vs 46%), which is surprisingly low, given reported mortality rates in other critically ill 
COVID-19 cohorts, suggesting a rather loose definition of “critical illness”.
Our cohort of patients had a higher 30-day mortality rate compared to a similar study by Giacomelli et al. 
(46% vs. 20.6%)23. This could be explained by the older age of our cohort (median 75 vs. 61 years) and the differ-
ent setting- ours being a large district general hospital whilst the other was a specialist infectious disease hospital. 
However, our mortality rate is reflective of data obtained in 16,749 hospitalised UK patients of similar age to 
 ours24. Baseline characteristics predictive of mortality in our cohort were similar to those previously reported, 
Table 3.  Multivariable logistic regression analysis. AF Atrial Fibrillation, mSIC modified Sepsis-Induced 
Coagulopathy score. Bold values indicate p < 0.05.
Odds ratio 95% CI p-value
Age ≥ 75 years 3.84 2.25–6.83 < 0.001
Male 1.88 1.06–3.21 0.026
Hypertension 1.40 0.82–2.40 0.218
Coronary artery disease 1.62 0.76–4.07 0.273
Heart failure 0.87 0.39–2.13 0.750
AF 0.49 0.35–1.58 0.137
Oral anticoagulants 2.08 0.81–5.41 0.130
mSIC score 2.37 1.79–3.14 < 0.001
Table 4.  The COVID-19 mortality score for predicting 30-day outcome in hospitalised patients. The score is 
derived from a multivariable regression analysis of independently predictive variables.
COVID19 mortality score
Components Points
Modified sepsis-induced coagulopathy (mSIC) score
INR
≤ 1.2 0




≥ 100 and < 150 1
< 100 2
qSOFA score
GCS < 15 1
RR > 22 1
Systolic BP < 100 1
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Figure 1.  The COVID-19 mortality score adjusted prediction of 30-day mortality, with 95% CI.
Table 5.  Usefulness of the COVID-19 mortality score for predicting 30-day death. PPV positive predictive 
value, NPV negative predictive value.
COVID-19 mortality score Sensitivity (%) Specificity (%) PPV (%) NPV (%)
≥ 1 100 12.3 50.8 100
≥ 2 95.2 35.1 55.6 89.6
≥ 3 80 60.2 63.0 78.0
≥ 4 67.6 78.4 72.6 74.0
≥ 5 39.3 93.6 83.8 64.5
≥ 6 13.1 97.7 82.6 57.0
≥ 7 3.5 100 100 56.8
≥ 8 1.4 100 100 54.5
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namely older age, male gender, hypertension and cardiovascular disease. As many of these conditions co-exist in 
elderly patients, the multivariable logistic regression used provides evidence that after adjustment, the only vari-
ables that remain independently predictive of 30-day mortality were age, gender and the mSIC score. Individuals 
with diabetes and black, Asian and minority ethnic (BAME) groups were under-represented in our cohort and 
so suitable conclusions on these risk factors cannot be drawn from our data.
Importantly, no risk score calculator will be 100% accurate. Therefore, such a scoring system can at best 
serve as an adjunct to decision-making during admission and can be used to identify those at high risk who may 
require more careful review and earlier intervention, and to guide and explain prognosis to relatives who may 
find that being quoted an objective survival rate based on the score may help better prepare them for the future.
Limitations. There are a number of limitations in our study. Firstly, as retrospective study, bias and con-
founders that are not identified cannot be addressed, and patients at the highest risk may be deemed too sick for 
maximal intervention and may be denied ICU treatment. Prediction of mortality was made retrospectively with 
knowledge of outcome data which introduces bias. The predictors and their assigned weights in the final model 
did not exactly correspond to those reported in the multivariable analysis, but have been rounded to whole 
numbers to make the score easier to use. Ours is a relatively small cohort from a single UK centre, and we can-
not know whether our predictive model applies equally to other geographies and healthcare models, to patients 
with diabetes, or to those in BAME groups or other ethnicities. Finally, our proposed predictive model requires 
external, independent validation in a large prospective cohort.
Conclusion
We have developed a simple, easy-to-use risk score calculator for patients admitted to hospital with COVID-19, 
which is a strong predictor of 30-day mortality. Whilst the score requires further external validation, it has the 
potential to guide prognosis for family and friends and to identify patients at increased risk, who may require 
closer observation and more intensive or earlier intervention.
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